Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
11. Juni 2024 08:20 ET
|
Processa Pharmaceuticals, Inc.
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses...
Oncology Nutrition Market Experiences Growth with Rise in Personalized and Immuno-nutrition Trends
22. Januar 2024 21:28 ET
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Oncology Nutrition Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The recent comprehensive analysis within...
Medicovestor, Inc announces the completion of an oversubscribed Seed Financing round to advance its novel Antibody Drug-Conjugate (ADC) platforms
20. November 2023 10:00 ET
|
Medicovestor Inc
Medicovestor excels in oversubscribed Seed funding for its novel Anti-Drug Conjugate (ADC) platforms, gearing up for Series A in H1 2024.
Cancer Advances, Inc. Announces Issuance of New U.S. Patent
28. Februar 2023 02:00 ET
|
Cancer Advances Inc
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S....
The Worldwide Endoluminal Suturing Devices Industry is Expected to Reach $152.3 Million by 2028
11. November 2022 04:33 ET
|
Research and Markets
Dublin, Nov. 11, 2022 (GLOBE NEWSWIRE) -- The "Global Endoluminal Suturing Devices Market Size, Share & Industry Trends Analysis Report By Application (Gastrointestinal Surgery, Bariatric...
Global Oncology Nutrition Market Report 2022: A $2.13 Billion Market in 2026 Featuring B. Braun Melsungen, Danone India, Abbott Laboratories, Nestle, Victus
06. Oktober 2022 06:13 ET
|
Research and Markets
Dublin, Oct. 06, 2022 (GLOBE NEWSWIRE) -- The "Oncology Nutrition Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global oncology nutrition market is...
Tyrokinse Kinase Inhibitors in the Global Oncology Market 2021: Market Leaders by Indication and Product
05. November 2021 05:58 ET
|
Research and Markets
Dublin, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The "Oncology Markets for Tyrokinse Kinase Inhibitors" report has been added to ResearchAndMarkets.com's offering. Traditional cancer therapy has focused...
Cancer Advances, Inc. Announces Publication, “Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model" in Cancer Prevention Research
24. August 2021 10:30 ET
|
Cancer Advances Inc
DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces a new publication in...
Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer
04. August 2021 08:30 ET
|
Processa Pharmaceuticals, Inc.
Processa’s Phase 1b open label, multicenter trial is currently enrolling patients who have advanced, relapsed GI cancer that are refractory or intolerant to other therapies and are candidates for...
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstracts at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
28. April 2021 12:35 ET
|
Provectus Biopharmaceuticals Inc.
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors (NCT02693067) — Systemic administration of PV-10 for treatment of solid tumor...